Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Ivosidenib

Ivosidenib Phase 1 (glioma)

Servier · Phase 1 · Completed · Enrollment 174

NCT02073994

ArmReported safety
Ivosidenib, non-enhancing glioman/r

A count stays a count. This page does not turn a count into a percent.